The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

Netflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

We’re firmly in the “buyer beware” era of obesity drugs. And unfortunately, it seems like we’re going to be stuck here for a ...

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

The Federal Trade Commission Friday announced it was suing the country's three biggest pharmacy benefit managers, claiming unfair practices inflated the cost of insulin.

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.